As of 2026-09-12, the Fair Value of Supernus Pharmaceuticals Inc (SUPN) is -47.33 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 41.64 USD, the upside of Supernus Pharmaceuticals Inc is -213.67%.
With the market price of 41.64 USD and our fair value calculation, Supernus Pharmaceuticals Inc (SUPN) is not a good investment. Investing in SUPN stocks now will result in a potential loss of 213.67%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | 53.40 | 60.70 | 1.32 | 73.86 | -38.55 | 30.15 |
| YoY growth | -57.95% | 13.67% | -97.83% | 5,512.84% | -152.19% | 1,043.71% |
| Market Cap (mil) | 2,416.79 |
| P/E | |
| Forward P/E |
| EPS | -1.89 |
| Avg earnings growth rate | 1,043.71% |
| TTM earnings | -109.89 |